| Epidaza (chidamide) / Chipscreen |
NCT04511351: Radiotherapy Combined With GDP With or Without Chidamide in Stage I/II Extranodal Nasal NK/T-cell Lymphoma |
|
|
| Recruiting | N/A | 76 | RoW | Chidamide | Chinese Academy of Medical Sciences | Lymphoma | 12/20 | 12/20 | | |
ChiCTR1800014269: Clinical study on maintain treatment of chidamide in peripheral T cell lymphoma after autologous peripheral hematopoietic stem cell transplantation |
|
|
| Recruiting | N/A | 66 | | maintain treatment of chidamide | Department of Hematology, Xinqiao Hospital, Third Military Medical University; Xinqiao Hospital, National Nature Science Fund 81500147 | peripheral T cell lymphoma | | | | |
NCT05047848: Clinical Study of Chidamide Combined With Fulvestrant in the Treatment of Hormone Receptor-positive Advanced Breast Cancer |
|
|
| Recruiting | N/A | 82 | RoW | Chidamide, Fulvestrant | Liaoning Tumor Hospital & Institute | Advanced Breast Cancer | 06/22 | 09/23 | | |
ChiCTR2000032330: Study for chidamide and descitabine plus interferon in the treatment of early relapse of acute leukemia post hematopoietic stem cell transplantation |
|
|
| Recruiting | N/A | 30 | | Chidamide and descitabine plus interferon | Sichuan Academy of Medical Sciences Sichuan Provincial People's Hospital; Sichuan Academy of Medical Sciences Sichuan Provincial People's Hospital, Science and Technology Department of Sichuan Province | acute leukemia | | | | |
NCT04582955: Neoadjuvant Treatment of Early Triple-negative Breast Cancer With Chidamide and Chemotherapy |
|
|
| Recruiting | N/A | 20 | RoW | Chidamide in combination with chemotherapy, Other Name: For Chidamide: HBI-8000, CS055 | Tianjin Medical University Cancer Institute and Hospital | Triple-negative Breast Cancer | 12/22 | 12/22 | | |
ChiCTR1900026419: Chidamide combined with decitabine treating acute myeloid leukemia in the elderly, a single-center, single-arm, open and prospective clinical trial |
|
|
| Not yet recruiting | N/A | 50 | | Desitabine combined with chidamide | The First Affiliated Hospital of Harbin Medical University; The First Affiliated Hospital of Harbin Medical University, Self-collected | Acute myeloid leukemia | | | | |
ChiCTR1900026796: Clinical observation for the treatment of acute myeloid leukemia in aged patients with citabine combined with cytarabine |
|
|
| Not yet recruiting | N/A | 50 | | citabine combined with azacitidine | The First Affiliated Hospital of Harbin Medical University; The First Affiliated Hospital of Harbin Medical University, Self-collected | Acute myeloid leukemia | | | | |
ChiCTR2100043966: A study for combined with chidamide miantenance therapy after chidamide and azacitidine+CHOP sequential autologous hematopoietic stem cell transplantation in the first diagnosised III / IV stage peripheral T cell lymphoma |
|
|
| Recruiting | N/A | 30 | | combined with chidamide miantenance therapy after chidamide and azacitidine+CHOP sequential autologous hematopoietic stem cell transplantation | Chongqing University Cancer Hospital; Chongqing University Cancer Hospital, self -collected | peripheral T cell lymphoma | | | | |
ChiCTR2100048715: Clinical trial of Chidamide in combination with Anlotinib for refractory and advanced soft tissue sarcoma after failure of standard therapy |
|
|
| Not yet recruiting | N/A | 56 | | Treatment was performed according to the combination regimen of cidabentamine and amlotinib | Shanghai Sixth People's Hospital; Shanghai Sixth People's Hospital, Shanghai Sixth People's Hospital | soft tissue sarcoma | | | | |
NCT05137522: Chidamide Combines With VP-16 and Methylprednisolone in the Treatment of HLH |
|
|
| Recruiting | N/A | 20 | RoW | Chidamide combines with VP-16 and methylprednisolone | Beijing Friendship Hospital | Chidamide, Hemophagocytic Lymphohistiocytosis | 07/23 | 07/23 | | |
NCT05478473: Clinical Study of Chidamide Combined With Toripalimab in the Treatment of Advanced Melanoma |
|
|
| Recruiting | N/A | 43 | RoW | Chidamide combined with Toripalimab | Peking University Cancer Hospital & Institute | Melanoma | 08/23 | 08/24 | | |
| Recruiting | N/A | 50 | RoW | Chi-GVM, Chidamide Combined With Gemcitabine, Vinorelbine, and Mitoxantrone Hydrochloride Liposome | The First Affiliated Hospital with Nanjing Medical University | Relapsed/Refractory Peripheral T-cell Lymphoma | 09/25 | 09/25 | | |
NCT05772728: Chidamide Combined With Azacitidine and Mitoxantrone Liposome in the Treatment of Relapsed/Refractory (nTFHL) |
|
|
| Not yet recruiting | N/A | 23 | NA | Cidapenem combined with azacitidine and mitoxantrone liposome (CAM) regimen, CAM | The First Affiliated Hospital with Nanjing Medical University | T Cell Lymphoma | 12/23 | 12/24 | | |
NCT05784987: R-MINE+X in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma |
|
|
| Not yet recruiting | N/A | 60 | NA | Rituximab, Mitoxantrone hydrochloride liposome, Isophosphamide, Etoposide, X: Orelabrutinib, X: Chidamide, X: Penpulimab, X: Lenalidomide | The First Affiliated Hospital with Nanjing Medical University | Diffuse Large B-cell Lymphoma | 01/24 | 01/25 | | |
CPABC, ChiCTR2000029509: Chidamide for patients with advanced breast cancer: a multi-center, prospective real world study |
|
|
| Not yet recruiting | N/A | 2000 | | Patients who have failed treatment with tamoxifen or aromatase inhibitors: Chidamide and Fulvestrant ;Patients who have not been treated or failed treatment with tamoxifen: Chidamide and aromatase inhibitors ;Triple-negative and Her-2 positive patients: Chidamide and PD-1 or anti-Her-2 treatment | The Fifth Medical Centre of Chinese PLA General Hospital; Harbin Medical University Cancer Hospital, self-raised | advanced breast cancer | | | | |
NCT06386302: Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia |
|
|
| Not yet recruiting | N/A | 184 | NA | Chidamide, Venetoclax, azacitidine | Institute of Hematology & Blood Diseases Hospital, China | AML, Acute Myeloid Leukemia | 12/27 | 12/27 | | |
ChiCTR2100053797: A single arm exploring study on the efficacy and safety of Chidamide Tablets maintenance for prevention of T/NK cell tumor recurrence after allogeneic hematopoietic stem cell transplantation |
|
|
| Recruiting | N/A | 54 | | Chidamide Tablets | Tongji Hospital affiliated to Tongji Medical College, Huazhong University of Science and Technology; Tongji Hospital affiliated to Tongji Medical College, Huazhong University of Science and Technology, Shenzhen Chipscreen Biosciences Co.,Ltd. | T/NK cell tumor | | | | |
ChiCTR2100052798: Efficacy observation of Chidamide combined with PD-1 monoclonal antibody after CART for relapsed/refractory B-cell lymphoma—a prospective, single-center, single-arm clinical study |
|
|
| Recruiting | N/A | 25 | | Chidamide Tablets combined with PD-1 | Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology; Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Shenzhen Chipscreen Biosciences Co.,Ltd. | relapsed/refractory B-cell lymphoma | | | | |
ChiCTR2300074093: Prospective, single arm, single center study of Duvaliser combined with Cedarbamide in the treatment of newly treated peripheral T-cell lymphoma (PTCL) |
|
|
| Not yet recruiting | N/A | 36 | | duvelisib+Chidamide | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, CSPC OUYI PHARMACEUTICAL CO., LTD. | peripheral T-cell lymphoma (PTCL) | | | | |
ChiCTR2300068737: An exploratory, prospective, one arm, open-ended study of immunoradiotherapy combined with chidamide and sintilimab in the treatment of HER2 negative advanced breast cancer |
|
|
| Not yet recruiting | N/A | 35 | | immunoradiotherapy combined with chidamide and sintilimab | Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School; Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, raise independently | breast cancer | | | | |
NCT05896813: CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma |
|
|
| Recruiting | N/A | 30 | RoW | CMOP+Chidamide | The First Affiliated Hospital with Nanjing Medical University | Newly Diagnosed Peripheral T-cell Lymphoma | 01/25 | 01/25 | | |
ChiCTR2200057712: Epigenetic-guided clinical trial of sidarbenamine combined with R-CHOP in the initial treatment of B-cell lymphoma |
|
|
| Recruiting | N/A | 92 | | Chidamide Combined with R-CHOP Regimen | Peking University Third Hospital; Peking University Third Hospital, self-funded | lymphoma | | | | |
ChiCTR2000034301: A single-center, prospective, real-world study of chidamide in combination therapy for advanced breast cancer |
|
|
| Not yet recruiting | N/A | 100 | | Chidamide and combination drug | West China Hospital, Sichuan University; West China Hospital, Sichuan University, Self-collected | advanced breast cancer | | | | |
MM-C01, ChiCTR2000035100: A prospective, single-arm, exploratory clinical study on the treatment of refractory and relapsed multiple myeloma (MM) patients with Chidamide combined with Thalidomide, Cyclophosphamide and Dexamethasone (TC2D) |
|
|
| Recruiting | N/A | 66 | | Chidamide combined with Thalidomide, Cyclophosphamide and Dexamethasone | The First Affiliated Hospital of Medical College of Zhejiang University; The First Affiliated Hospital of Medical College of Zhejiang University, Self-raised | Multiple Myeloma | | | | |
ChiCTR2300077213 : This is a single-arm, exploratory clinical study on the treatment of advanced colorectal cancer as third-line and beyond with a standard third-line regimen (TAS102± bevacizumab/regorafenib/furoquininib) |
|
|
| Not yet recruiting | N/A | 30 | | Chidamide + slulizumab + standard third-line regimen (TAS102± bevacizumab/regorafenib/fuquinitinib) | First affiliated hospital of Soochow university | Colorectal cancer | | | | |
NCT05967949: A Retrospective Clinical Study on the First-line Maintenance Treatment of PTCL With Chidamide. |
|
|
| Recruiting | N/A | 200 | RoW | chidamide | The First Affiliated Hospital with Nanjing Medical University | PTCL | 04/26 | 04/28 | | |
NCT05890287: A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line Chemotherapy |
|
|
| Recruiting | N/A | 60 | RoW | Chidamide, exemestane, Fulvestrant, Letrozole, Anastrozole, Tamoxifen | Tianjin Medical University Cancer Institute and Hospital | HR Positive HER2 Negative Advanced Breast Cancer | 05/26 | 10/26 | | |
NCT06066905: A Study of Chidamide With AZA in MRD Positive AML After Transplant |
|
|
| Recruiting | N/A | 60 | RoW | chidamide and azacitidine | Guangdong Provincial People's Hospital, Shenzhen Chipscreen Biosciences Co.Ltd | AML, Adult, Minimal Residual Disease | 12/26 | 12/26 | | |
